Experimental Drug Shows Promise as Possible Coronavirus Treatment
Summary from the AllSides News Team
Featured Coverage of this Story
From the Center
Trump wants FDA to move ‘as quickly as they can’ on remdesivir coronavirus approval
President Donald Trump said Wednesday that he wants the Food and Drug Administration to move “as quickly as they can” to approve Gilead Sciences’ antiviral drug remdesivir as a treatment for the coronavirus.
“We would like to see very quick approvals, especially with things that work,” he said at a roundtable at the White House with business executives Wednesday evening.
Earlier in the day, the FDA said it has been in “sustained and ongoing” discussions with Gilead to make remdesivir available to Covid-19 patients “as quickly as possible, as appropriate.”...
From the Right
Experimental coronavirus treatment remdesivir delivers 'positive data' in trial, says developer Gilead
The experimental coronavirus treatment remdesivir has generated “positive data” in a trial of the antiviral organized by the National Institute of Allergy and Infectious Diseases (NIAID), according to developer Gilead Sciences.
“We understand that the trial has met its primary endpoint and that NIAID will provide detailed information at an upcoming briefing,” said Gilead in a statement released Wednesday.
The NIAID study is a double-blind placebo-controlled trial encompassing more than 800 patients, according to a recent document posted by Gilead on its website. The study involves patients with critical, severe...
From the Left
Hopes build over Gilead drug as global case count grows
An experimental antiviral drug to treat COVID-19 patients has fanned high expectations in the fight against the coronavirus pandemic, which has gained a decisive foothold in the United States and continues to spread around the world.
Gilead Sciences (GILD) acknowledged Wednesday that its drug, remdisivir, has seen positive results in both a company-sponsored and National Institute of Health-run study — with the federal regulators reportedly prepared to bestow emergency approval on the drug, according to The New York Times.
The treatment has been a frontrunner in the treatment race for...
AllSides Picks
April 24th, 2024
April 22nd, 2024
More News about Healthcare from the Left, Center and Right
From the Left
From the Center
From the Right
